Doença falciforme: um estudo sobre os custos de três eixos terapêuticos no Brasil
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora (UFJF)
Abstract
Sickle Cell Disease (SCD) is the most prevalent single-gene disease in the
world, with a great impact on public health. The pathology has high morbidity and
mortality. As it presents heterogeneous clinical manifestations, according to severity,
SCD requires treatments with a variable impact on the budget of the Unified Health
System (SUS). The main scope of follow-up and treatment of sickle cell patients
revolves around basic care in the first years of life, which includes specialized medical
follow-up, infectious prophylaxis with antibiotics and vaccines, continuous use of Folic
Acid, complementary exams, a protocol for the prevention of stroke (Transcrian
Doppler), among other actions. In addition, it is important to mention the transfusional
support, which – is fundamental for the disease control and the hospitalizations, since
SCD patients are hospitalized several times throughout their lives. This research aims
to determine the direct medical costs of these three therapeutic axes of SCD in Brazil.
In order to accomplish this objective, we use different methodologies and databases
for data analysis. We only used data from public sources for the measurement of
expenses related to basic prophylactic care in children with sickle cell disease up to
five years of age and those related to hospitalizations. For the analysis of transfusion
costs, we used the basis of the Recipient Epidemiology and Donor Evaluation-III
(REDS-III) Brazil SCD Cohort. This is a cohort created to define the prevalence of
clinical complications with a focus on transfusion outcomes in a large sample of the
Brazilian population with SCD and to create the infrastructure to carry out targeted
studies within the cohort. In all three investigations, the cost perspective adopted was
that of the financing SUS (payer). These costs are paid by the health system to the
service providers and the referral centers for the treatment of SCD, as it is the case of
Blood Centers. Direct medical costs (consultations, exams, medication, etc.) were
included in these analyses. Direct non-medical costs (companions, rehabilitation, etc.)
and indirect costs (loss of productivity) were not included. We conclude that antibiotic
prophylaxis, extended active immunization, multidisciplinary follow-up and the
Transcranial Doppler Protocol are examples of effective and already implemented
public policies that have a positive impact on the quality of life of children with SCD.
We observed that morbidity and mortality reduce, the costs are considerably lower
than those of transfusion therapy and expenses with hospital admissions due to
disease complications. There was a huge gap in the scientific literature regarding costs
related mainly to prophylactic care and transfusion therapy in SCD, making it difficult
to compare results. Given the lack of studies on the subject in question, the data
generated here can be used to calibrate the criteria adopted in future studies and help
to encourage discussion about the important costs related to SCD.
Description
Citation
Collections
Endorsement
Review
Supplemented By
Referenced By
Creative Commons license
Except where otherwise noted, this item's license is described as Acesso Aberto

